Back to Search
Start Over
[Expression of epidermal growth factor receptor (EGFR) in ovarian carcinoma stage III-IV].
- Source :
-
Voprosy onkologii [Vopr Onkol] 2005; Vol. 51 (3), pp. 361-5. - Publication Year :
- 2005
-
Abstract
- Hyperexpression of epidermal growth factor receptor (EGFR) is often identified as unfavorable prognosis for different epithelial cancers. The study was concerned with an attempt of establishing a relationship between EGFR expression, on the one hand, and patient's clinico-morphological status, prognosis and efficacy of chemotherapy for stage III-IV serous ovarian carcinoma, on the other. EGFR hyperexpression predominated in advanced aggressive tumors and involved a significantly shorter period preceding tumor progression. Similarly, overall survival median in patients with EGFR hyperexpression (21+/-4 months) appeared lower than without it (42+/-8 months). In serous ovarian carcinoma stage III-IV, EGFR hyperexpression should be considered sufficient for prognosis of chemotherapy efficacy, pre-progression time and survival.
Details
- Language :
- Russian
- ISSN :
- 0507-3758
- Volume :
- 51
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Voprosy onkologii
- Publication Type :
- Academic Journal
- Accession number :
- 16279103